Published in Drug Week, September 6th, 2002
The combination of the once-daily formulations of videx EC (didanosine, ddI), Epivir (lamivudine, 3TC [GlaxoSmithKline]), and Sustiva (efavirenz) therapy provides a new option for simplifying patients' medication schedules. Each drug is strongly recommended by the U.S. Department of Health and Human Services (DHHS) guidelines for use in first-line combination treatment of HIV-infected individuals.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.